- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04068909
ObseRvation After Acute Coronary Syndrome for deveLopment of trEatment Options (ORACLE)
Exacerbation of Coronary Heart Disease: the Logic and Probabilistic Processes of Flow Prediction for Optimization of Treatment
The aim of the study is developing an individualized risk model for the unfavorable outcomes of coronary artery disease and complications from ongoing therapy, according to clinical, instrumental, biochemical and genetic parameters in patients with acute coronary syndrome.
Inclusion criteria: patients with acute coronary syndrome (with or without ST elevation) who have indications for PCI Number of inclusion patients - 1655 patients Scheduled time of follow up - 24 month Primary end-point: all-cause death Secondary end-points: any cardiovascular events (cardiovascular death, nonfatal myocardial infarction, non-fatal stroke); non-fatal myocardial infarction; recurrent acute coronary syndrome; non-fatal stoke; complicated atherosclerosis; recurrent PCI; bleeding
Visão geral do estudo
Status
Condições
Descrição detalhada
The role of genetic factors in the development of coranary heart disease (CHD) exacerbations studied not enough. Most research in this area planned and carried out on a "case-control". Using a similar protocol entails significant errors are associated with a high incidence of subclinical atherosclerotic vascular lesions. Moreover, much of atheroma is extravasal, making it impossible to identify them by angiography. Therefore, necessary to conduct prospective studies to estimate the frequency of so-called hard endpoints. Previously, similar trials were conducted, mainly in connect with drug approving procedures. The spread data from them to other patients directly is not entirely justified. At the same time, the influence of genetic factors in this group of patients can be substantial.
In the previous part of the study, the sample of patients of Moscow, St. Petersburg, Kazan, Chelyabinsk, Stavropol, Perm, and Rostov-on-the-Don was formed, of 1,200 people admitted due to acute coronary syndrome (ACS) including unstable angina and acute myocardial infarction, at coronary care units with follow-up for three years. We found several factors, including genetic, that significantly affect the outcomes of the disease. Coronary atherosclerosis and its complications now considered as a multifactorial disease associated with inherent factors. Therefore, the project provides, besides accounting a significant amount of clinical and instrumental data, the determination of a wide range of genotypes and alleles of polymorphic markers candidate genes encoding the protein factors of the hemostatic system, enzymes of lipid metabolism system, and anti-inflammatory cytokines. It is assumed that the prediction outcomes of coronary heart disease should be carried out taking into account the fact that several factors (gender, diabetes, age, aortic stenosis, atrial fibrillation, etc.) can not only significantly change the forecast itself but also affecting the significance of other risk factors. Since the last study, the standards significantly of ACS management changed. Invasive treatment not only creates opportunities to reduce coronary mortality but also increased demands on the patient's adherence to the assigned medication and creates additional risks associated with its activity (especially with an antithrombotic treatment activity). In these circumstances, the development of personalized approaches to prescribing drugs is particularly important. Thus, the prediction of coronary heart disease outcomes after an ACS on a set of clinical, instrumental, biochemical and genetic indicators is of great importance, as it allows to plan the most optimal treatment for the individual patient.
The aim of the study was to develop a model of individualized risk of coronary heart disease outcomes and side effects of therapy based on clinical and instrumental, biochemical, and genetic parameters in patients with ACS.
Tipo de estudo
Inscrição (Real)
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
Patients with acute coronary syndrome without ST-segment elevation meeting the criteria of a very high, high or intermediate risk, and patients from the low-risk group, if they have episodes of myocardial ischemia in any way Very high risk (1 criterion is sufficient)
- Pulmonary edema, most probably due to ischemia.
- The newly appears or increased noise of mitral regurgitation.
- Rhythm of the gallop, newly developed or intensified wheezing in the lungs.
- Hypotension against ischemia
- Ischemia refractory to treatment
Persistent ventricular tachycardia or the occurrence of ventricular rhythm disturbances during an attack of ischemia High risk
(1 criterion is sufficient)
- An anginal attack more than 20 minutes within the next 48 hours before admission
- Transitional elevations ST (duration less than 20 min)
- GRACE score > 140 points
- Increased cardiospecific markers of necrosis. (you must have at least 2 criteria)
- Age> 75 years.
- Angina pectoris with transient changes ST> 0.05 mV.
Intermediate risk (1 criterion is sufficient)
- Age> 75 years.
- Angina pectoris with transient changes ST> 0.05 mV.
- Inversion of the T wave on ECG (≥ 0.2 mV).
- GRACE score 104-139 points
(it is necessary to have at least 2 criteria)
- Angina of rest (<20 min), stopped spontaneously or with the help of nitroglycerin (NG).
- Anamnesis of pathology of peripheral or cerebral arteries,
- Postponed myocardial infarction, including painless, history of revascularization (PCI or CABG)
- Diabetes.
- Chronic renal failure (GFR <50 mL / min)
Low risk All other patients with suspicion of ACS require a survey to identify episodes of ischemia
Patients with acute coronary syndrome with ST-segment elevation
Patients who were hospitalized with symptoms due to acute myocardial infarction (the duration of infarction is no more than 10 days, by the time of hospitalization) and at least one of the following additional criteria identified upon admission to hospital:
- ST elevation: a persistent ST increase of 1 mm in two adjacent leads from the limbs, or an ST increase of 2 mm in two adjacent thoracic leads
- the appearance of a new left bundle branch block
- dynamics of acute myocardial infarction
- Signed informed consent to participate in the study
Exclusion Criteria:
- Lack of patient consent to participate in the study
- Impossibility of contact with the patient after discharge after index event
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Coorte
- Perspectivas de Tempo: Prospectivo
Coortes e Intervenções
Grupo / Coorte |
---|
acute coronary syndrome
All patients should receive standard therapy for acute coronary syndrome and concomitant diseases.
All drugs are prescribed according current guidelines and approved indications.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
all-cause death
Prazo: Number of Participants with end-point during 360 days
|
death from any cause
|
Number of Participants with end-point during 360 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
cardiovascular events
Prazo: Number of Participants with end-point during 360 days
|
cardiovascular death, non-fatal myocardial infarction, non-fatal stroke
|
Number of Participants with end-point during 360 days
|
non-fatal myocardial infarction
Prazo: Number of Participants with end-point during 360 days
|
non-fatal myocardial infarction
|
Number of Participants with end-point during 360 days
|
recurrent acute coronary syndrome
Prazo: Number of Participants with end-point during 360 days
|
all cases of recurrent myocardial infarction or unstable angina after the index events
|
Number of Participants with end-point during 360 days
|
recurrent PCI
Prazo: Number of Participants with end-point during 360 days
|
all cases of recurrent PCI after the index hospitalization
|
Number of Participants with end-point during 360 days
|
complicated atherosclerosis
Prazo: Number of Participants with end-point during 360 days
|
peripheral atherosclerosis need hospitalisation
|
Number of Participants with end-point during 360 days
|
non-fatal stroke
Prazo: Number of Participants with end-point during 360 days
|
all cases of non-fatal stroke
|
Number of Participants with end-point during 360 days
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
bleeding
Prazo: Number of Participants with end-point during 360 days
|
all cases of bleeding during and after the index hospitalization
|
Number of Participants with end-point during 360 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Dmitry A Zateyshchikov, prof, Central State Medical Academy
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ORACLE-II
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .